Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AllerT dose-finding for birch pollen allergy
NCT02271009Phase 2Completed
- Sponsor
- Anergis
- Start
- Oct 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cetirizine in allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by Anergis. Primary endpoint: Total Rhinoconjunctivitis Symptom Score at 6 hours. Started Oct 2014; status: completed.
02
Drugs
cetirizine
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT02271009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02271009.